HBOT and Stroke Recovery: What the Efrati 2013 Trial Did and Did Not Show
A 2013 trial reported neurological gains from HBOT in chronic stroke patients. It is an intriguing signal, but major guidelines have not adopted HBOT for stroke. An honest read.
A question that keeps coming back
Few uses of hyperbaric oxygen therapy generate more hope, or more overstatement, than stroke recovery. The idea is that raising oxygen delivery to injured brain tissue might reactivate cells that are damaged but not dead, even long after the stroke. The study most often cited in support is a 2013 randomized trial by Efrati and colleagues, published in PLOS ONE, and it deserves to be read carefully rather than quoted as a headline.
It is worth stating the conclusion up front: this is a single, small trial with an interesting signal, and it has not changed how stroke is treated in mainstream guidelines.
What the trial did
The trial enrolled 74 patients who had suffered a stroke between 6 and 36 months earlier, so all were in a chronic, late stage rather than the acute phase. It used a crossover design in which one group received 40 hyperbaric sessions over about two months while the other group first went through a two-month control period with no treatment, then received the same 40 sessions. Outcomes were assessed with the NIHSS neurological scale, activities of daily living, quality-of-life measures, and SPECT brain imaging.
The authors reported that neurological function and quality of life improved significantly after the HBOT sessions, with no improvement during the untreated control period. They described 43 percent of patients showing significant functional improvement and a further 29 percent showing mild improvement, and interpreted the imaging as evidence that neuroplasticity can be activated at a chronic stage.
Why caution is warranted
The limitations are important and the authors did not hide the design. The study was small and conducted at a single center, and the crossover control was a period of no treatment rather than a sham or placebo procedure, so patients knew they were being treated. That leaves the results vulnerable to expectation effects and makes them hard to separate from placebo influence. The findings have not been reproduced in large, blinded, multicenter trials.
This is why the result should be treated as hypothesis-generating. It is a reason for more research, not proof of benefit.
What the guidelines actually say
Crucially, major stroke guidelines have not adopted hyperbaric oxygen therapy as a recommended treatment for stroke or stroke rehabilitation, and stroke does not appear on the recognized hyperbaric indication lists. Anyone told that HBOT is an established stroke therapy is being given a picture that runs ahead of the evidence.
Because stroke is heavily marketed to consumers considering home devices, it is a setting where scrutiny pays off, and a neutral primer at buying guide can help separate device sales from clinical claims. The equipment being real does not make an unproven use proven.
Stroke rehabilitation is a long, individualized process directed by neurology and rehabilitation specialists. Whether HBOT has any role for a specific person is a question for those treating physicians, made with clear eyes about how limited the current evidence is.